Human IL-2 as a vaccine adjuvant

Details Human IL-2 as a vaccine adjuvant Human IL-2 as a vaccine adjuvant

1995-05-24

1997-07-01

Ulm, John

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

514885, A61K 3820

Patent

active

056435657

ABSTRACT:
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.

REFERENCES:
patent: 5100664 (1992-03-01), Doyle et al.
Weinberg et al. (1988). J. Immunol. vol. 140, No. 1, pp. 294-299.
Donshue et al. (1984) Cancer Research. vol. 44, pp. 1380-1386.
Creekmore et al. (1989) J. Clinical Oncology, vol. 7, No. 2, pp. 276-284.
Kakumu et al. (1988) J. Clin. Lab. Immunol. vol. 26 pp. 25-27.

Affiliated with

Also associated with

Rating

Human IL-2 as a vaccine adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human IL-2 as a vaccine adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human IL-2 as a vaccine adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-594683